Assembly Biosciences (ASMB) said late Tuesday it has closed its underwritten offering of more than 3.9 million shares at $26.50 apiece, including the full exercise of an over-allotment option.
The company also said it sold to an existing investor pre-funded warrants to buy up to 415,000 shares.
Gross proceeds of about $115 million will be used to fund clinical development and for general corporate purposes, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.